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Abstract
Background: Idiopathic pulmonary fibrosis (IPF) often accompanies lung cancer, and life-threatening acute
exacerbation (AE) of IPF (AE-IPF) is reported to occur in 20 % of IPF patients who undergo lung cancer surgery.
Pirfenidone is an anti-fibrotic agent known to reduce disease progression in IPF patients. A phase II study was
conducted to evaluate whether perioperative pirfenidone treatment could reduce the incidence of postoperative
AE-IPF patients with lung cancer.
Methods: Pirfenidone was orally administered to IPF patients who were candidates for lung cancer surgery; pirfenidone
was dosed at 600 mg/day for the first 2 weeks, followed by 1200 mg/day. Surgery was performed after at least 2 weeks
of 1200-mg/day administration. The primary endpoint was non–AE-IPF rate during postoperative days 0–30, compared
to the null value of 80 %, and the secondary endpoint was safety. Radiologic and pathologic diagnoses of IPF and AE-IPF
were confirmed by an independent review committee.
Results: From June 2012 to January 2014, 43 cases were enrolled, and 39 were eligible (full analysis set [FAS]). Both
pirfenidone treatment and surgery were performed in 36 patients (per protocol set [PPS]). AE-IPF did not occur in 37/39
patients (94.9 % [95 % confidential interval: 82.7–99.4 %, p = 0.01]) in the FAS, and in 38/39 patients (97.2 % [95 %
confidential interval: 85.5–99.9 %, p = 0.004] in the PPS. A grade 5 adverse event (death) occurred in 1 patient,
after AE-IPF; no other grade 3–5 adverse events were observed.
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Conclusions: Perioperative pirfenidone treatment is safe, and is promising for reducing AE-IPF after lung cancer
surgery in IPF patients.
Trial registration: This clinical trial was registered with the University Hospital Medical Information Network
(UMIN) on April 16th, 2012 (Registration Number: UMIN000007774).
Keywords: Idiopathic pulmonary fibrosis, Acute exacerbation, Lung cancer, Surgery, Pirfenidone
Background
Idiopathic pulmonary fibrosis (IPF) is the most
common interstitial lung disease, and has a histo-
logical appearance of usual interstitial pneumonia
(UIP). IPF is known to be a risk factor for lung
cancer [1] and is often observed in lung cancer
patients. Life-threatening acute exacerbation (AE) of
IPF (AE-IPF) may occur in association with cancer
treatment, including radiotherapy, chemotherapy, and
surgery, thereby severely restricting the therapeutic
options for IPF-associated lung cancer. Among IPF
patients who undergo surgery for lung cancer, postop-
erative AE-IPF is reported to occur in approximately 20 %,
with an associated mortality of about 50 % [2–5]. Accord-
ing to nationwide research conducted by the Japanese
Association of Thoracic Surgery, AE-IPF is the leading
cause of death within 30 days after lung cancer surgery in
Japan [6]. Thus far, no reports of successful preventative
methods for postoperative AE-IPF have been published.
Several treatments, including intraoperative fluid
balance control [7], postoperative ulinastatin [8], and
preoperative methylpredonisolone and sivelestat [9],
have been reported to have the potential to prevent
postoperative AE; however, these were all evaluated
in small, single-institute prospective or retrospective
studies. A Japanese multi-institutional retrospective
large cohort study revealed that none of the potential
prophylactic treatments tested, including steroids,
sivelestat, and ulinastatin, demonstrated an ability to
prevent AE [10].
The Assessment of Pirfenidone to Confirm Efficacy
and Safety in Idiopathic Pulmonary Fibrosis (ASCEND)
study group recently reported that pirfenidone, oral
anti-fibrotic agent, significantly reduced disease pro-
gression, as reflected by lung function, exercise toler-
ance, and progression-free survival, in a phase III trial
in patients with IPF [11, 12]. However, with respect to
postoperative AE-IPF, the utility of pirfenidone has not
yet been evaluated. Therefore, we conducted the phase
II West Japan Oncology Group (WJOG) 6711 L study,
called the “Perioperative pirfenidone for lung cancer
with fibrosis evaluation: PEOPLE study,” to evaluate the
safety and efficacy of perioperative pirfenidone treatment




Patients were required to have the UIP/possible UIP
pattern criteria published by ATS/ERS/JRS/ALAT in
2011 [13] by high-resolution computed tomography
(HR-CT). Other inclusion criteria were: age 20 to
75 years; cytological, histological, or radiological diag-
nosis of non-small cell lung cancer; tolerability of
general anesthesia; cancer lesion(s) resectable by single
lobectomy or lesser resections; predicted post-surgical
forced expiratory volume in 1 second ≥1000 mL; able
to receive orally administered drugs; and Eastern
Cooperative Oncology Group performance status 0–1.
Patients were ineligible if they had a history of previous
thoracotomy/video-assisted thoracoscopic surgery
(although patients who had a history of surgical biopsy
for diagnosing IPF >6 months previously were accepted);
history of IPF treatment (including pirfenidone, steroids,
erythromycin, N-acetyl cysteine, neutrophil elastase
inhibitors, and immunosuppressants); history of radiation
therapy that included a lung in the treatment field or
chemotherapy; other known causes of interstitial pneu-
monia (e.g., environmental exposure, connective tissue
disease, and drug toxicity); severe comorbidities (active
infectious disease, severe heart disease, uncontrolled
diabetes mellitus, gastrointestinal bleeding, glaucoma,
or psychiatric disease); history of drug allergy; or
obvious history of acute exacerbation of IPF. Patients
receiving oxygen therapy and pregnant or breastfeeding
women were also excluded.
Study design
This was a multicenter, single-arm phase II study designed
to evaluate the efficacy of perioperative pirfenidone
treatment on the reduction of postoperative AE-IPF in
Japanese patients with lung cancer. The primary endpoint
was non–AE rate during postoperative days 0–30, and the
secondary endpoint was safety. The expected non–AE rate
was set at 95 %, and the non–AEthreshold was set at
80 %, because the non–AE rate in patients who did not
receive perioperative pirfenidone treatment was assumed
to be ≤80 % based on the literature [2–5, 14, 15]. A total
of 42 patients were determined to reject the non–AE rate
of 80 % under the expectation of 95 % with a power
of ≥0.80 and a one-sided alpha of 0.05.
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Central review
Radiologic and pathologic diagnoses of IPF-AE were
confirmed by a central review committee. To validate the
institutional diagnosis of IPF, preoperative HR-CT and
pathological samples obtained by surgery (non-cancerous
lesions) were collected from each participating institute
for central review. Two radiologists with expertise in
interstitial lung disease (S.S. and T.I.) initially evaluated
the HR-CT data independently and then developed a
consensus report after discussion. Two pathologists with
expertise in interstitial lung disease (J.F. and K.H.) initially
evaluated the pathological samples independently and
then developed a consensus report after discussion. These
experts followed the international IPF diagnostic criteria
published in 2011 [13]. The reports and discussions of the
radiological/pathological diagnoses were reviewed and
approved by all members of the central review committee,
including the radiologists, pathologists, respiratory physi-
cians with expertise in interstitial lung disease (A.A. and
K.K.), and surgeons (S.Y. and T.I.). If the final diagnosis by
HR-CT and pathological analysis was not definitively IPF,
a multidisciplinary discussion was conducted among
the radiologists, pathologists, respiratory physicians,
and surgeons, and this group made a final diagnosis
of IPF/not IPF.
Each participating institute diagnosed AE-IPF according
to the definition published by the Japanese Respiratory
Society [16] as follows: subjective worsening of dyspnea;
new-onset bilateral ground-glass attenuation; significant
worsening of partial pressure of oxygen in arterial blood;
and exclusion of alternative causes of dyspnea and
radiological changes, including pulmonary infection,
pneumothorax, worsening of malignant tumor, pulmon-
ary embolism, and heart failure. These criteria are very
similar to the definition of the American Thoracic
Society [17], although endobronchial aspiration and
bronchoalveolar lavage were not required. Each incidence
of postoperative AE-IPF declared by the researchers was
also evaluated by the central review committee. Central re-
view of HR-CT and clinical data were conducted through
multidisciplinary discussion to determine whether or not
the diagnosis of AE-IPF was appropriate.
Drug administration
Pirfenidone (Shionogi & Co., Ltd., Osaka, Japan) at a
dose of 600 mg/day was orally administered to patients
who planned to undergo surgery for the first 2 weeks;
the dose was then increased to 1200 mg/day for the next
2–4 weeks. The administration dose and dose-increase
interval were established according to the protocol
included in the Japanese pirfenidone package insert,
which was based on the results of the Japanese pre-
authorizing phase III trial [18]. Surgery was performed
after at least 2 weeks of administration of pirfenidone
1200 mg/day. Pirfenidone was given until the morning
of the surgery day, and then re-started at 1200 mg/day
as soon as oral administration was permitted; in most
cases, this was on the first postoperative day. The dose
was increased to 1800 mg/day if possible and was
continued for as long as possible at least until the 30th
postoperative day.
Analysis
In the primary analyses, the non–AE rate was based on
the full-analysis set (FAS) following the intent-to-treat
principle. P-values were calculated using binomial tests.
A p-value <0.05 was considered significant. All statis-
tical analysis was performed using SAS version 9.2
(SAS Institute, Cary, NC).
Results
Patient characteristics
From June 2012 to January 2014, 43 patients from 17
Japanese institutions were enrolled. Although all patients
initiated pirfenidone therapy, 4 patients were deemed
ineligible due to severe heart disease (n = 2), a history of
chemotherapy (n = 1), and initiation of pirfenidone prior
to registration (n = 1). Thus, 39 patients comprised the
FAS. Patients included 33 males (84.6 %) with a median
age of 68.0 (range, 52–75) years, and 38 patients had
Hugh-Jones grade I/II activity (97.5 %). Among the FAS
cases, two patients stopped pirfenidone administration
before surgery due to patient request, and surgery was
cancelled for one patient because metastatic lesions were
identified on further examination. Therefore, both pirfe-
nidone treatment and surgery were performed in 36
patients (per protocol set [PPS]). All of the PPS patients
had received pirfenidone 1200 mg/day for >2 weeks at
the time of surgery. The mean time at which pirfenidone
was stopped around surgery was 18.4 h. Characteristics
of FAS and PPS patients were very similar (Table 1). No
patients had a history of gastroesophageal reflux disease.
The surgical and pathological backgrounds are summa-
rized in Table 2. Lobectomy was performed in 26 FAS
patients (68.4 %) and 24 PPS patients (66.7 %). Segmen-
tectomy was performed in seven patients (FAS, 18.4 %;
PPS, 19.4 %), and wedge resection was performed in
seven patients (FAS, 18.4 %; PPS, 19.4 %). Combined
resections were performed in three patients (FAS, 7.9 %;
PPS, 8.3 %). Histologic types included squamous cell
carcinoma (FAS, n = 18 [47.4 %]; PPS, n = 18 [50 %]),
adenocarcinoma (FAS, n = 16 [42.1 %]; PPS, n = 14
[38.9 %]), and other minor types. Pathological cancer
stages included stage I/II (FAS, n = 22/12 [57.9 %/
31.6 %]; PPS, 20/12 [55.6 %/33.3 %]). With respect to
IPF diagnosis, the central review board diagnosed 39 of
the 43 registered cases as IPF and the remaining 4 cases
as not IPF (the latter were diagnosed as unclassifiable
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interstitial pneumonia [n = 2], cellular nonspecific inter-
stitial pneumonia [n = 1], and respiratory bronchiolitis-
associated interstitial lung disease [n = 1]). Compared to
the central review by the professional radiologist/path-
ologist/respirologist, the accuracy of the preoperative
radiological diagnosis of each institution was 90.7 %.
Four not-IPF cases were included in the FAS and the
PPS to adhere to the intent-to-treat principle. With
respect to efficacy, we also selected the confirmed IPF
cases from the PPS and analyzed them separately
(PPS-IPF, n = 32).
Safety
The safety of pirfenidone treatment in the preoperative
phase was evaluated in all patients who received pirfeni-
done (n = 43, safety analysis set) (Table 3). In the pre-
operative period, the following adverse events were
observed: photosensitivity (n = 1), anorexia (n = 4), nau-
sea (n = 4), somnolence (n = 1), dizziness (n = 2), malaise
(n = 2), anemia (n = 2), hypoalubuminemia (n = 2), alka-
line phosphatase elevation (n = 2), aspartate amino-
transferase elevation (n = 3), alanine aminotransferase
elevation (n = 3), γ-glutamyltransferase (GGT) elevation
(n = 5), creatinine elevation (n = 1), hyponatremia (n =
3), and hyperkalemia (n = 1); however, all of these
events were grade 1 or 2 according to the Common
Terminology Criteria for Adverse Events (CTCAE) ver-
sion 4.0 scale. Safety in the postoperative phase was
evaluated in 37 patients in the FAS who underwent sur-
gery. Fewer patients than those in the FAS who
underwent surgery were evaluated for postoperative
safety, because we did not require reporting of clin-
ical data, except for the occurrence of AE-IPF, for
patients who quit pirfenidone administration prior to
surgery. The following adverse events were observed
postoperatively: anorexia (n = 6), nausea (n = 3), diar-
rhea (n = 1), dizziness (n = 1), malaise (n = 2), respira-
tory failure (n = 1), dyspnea (n = 6), pulmonary fistula
(n = 2), postoperative hemorrhage (n = 1), cough (n =
1), atrial fibrillation (n = 1), wound dehiscence (n = 1),
pneumonitis (n = 1), dysgeusia (n = 1), white blood cell de-
creased (n = 2), neutrophil count decreased (n = 1), anemia
(n = 4), hypoalbuminemia (n = 19), alkaline phosphatase
increased (n = 8), blood bilirubin increased (n = 1), aspar-
tate aminotransferase increased (n = 8), alanine amino-
transferase increased (n = 6), GGT increased (n = 6),
hyponatremia (n = 8), hypokalemia (n = 3), and hypocalce-
mia (n = 3). Among these, 1 case of increased aspartate
Table 1 Patient characteristics
FAS (n = 39) PPS (n = 36)
Gender, M/F 33 (84.6 %)/6 (15.4 %) 30 (83.3 %)/6 (16.7 %)
Median age, years (range) 68.0 (52–75) 68.0 (52–74)
Smoking history, ex/never 38 (97.4 %)/1 (2.6 %) 35 (97.2 %)/1 (2.8 %)
Pack years 61.09 ± 32.07 61.85 ± 33.01
Body mass index 24.35 ± 3.43 24.41 ± 3.57
Activity
Hugh-Jones I 29 (74.4 %) 26 (72.2 %)
Hugh-Jones II 9 (23.1 %) 9 (25.0 %)
Hugh-Jones III 1 (2.6 %) 1 (2.8 %)
Hugh-Jones IV 0 (0.0 %) 0 (0.0 %)
Hugh-Jones V 0 (0.0 %) 0 (0.0 %)
Fine crackle (audible) 17 (43.6 %) 16 (44.4 %)
Vital capacity (%predicted) 96.51 ± 15.21 97.25 ± 15.25
FEV1.0 (% predicted) 92.31 ± 16.74 92.81 ± 17.24
DLCO (% predicted) 73.71 ± 23.11 73.88 ± 24.45
KL-6(U/mL) 1012.3 ± 891.9 1022.4 ± 924.7
DLCO diffusing capacity of the lung for carbon monoxide, FAS full analysis set,
FEV1.0 forced expiratory volume in 1 s, PPS per protocol set
Table 2 Patient surgical and pathological backgrounds
Surgical procedure FAS (n = 38) PPS (n = 36)
Operation time (hours) 3.36 ± 1.23 3.37 ± 1.25
Blood loss (g) 138.6 ± 126.2 127.7 ± 114.6
Surgical procedure
Lobectomy 26 (68.4 %) 24 (66.7 %)
Segmentectomy 7 (18.4 %) 7 (19.4 %)
Wedge resection 7 (18.4 %) 7 (19.4 %)
Combined resection 3 (7.9 %) 3 (8.3 %)
Residual tumor
R0 36 (94.7 %) 34 (94.4 %)
R1 1 (2.6 %) 1 (2.8 %)
R2 1 (2.6 %) 1 (2.8 %)
Cancer pathology FAS (n = 38) PPS (n = 36)
Pathological type
Squamous cell carcinoma 18 (47.4 %) 18 (50.0 %)
Adenocarcinoma 16 (42.1 %) 14 (38.9 %)
Large cell carcinoma 0 (0.0 %) 0 (0.0 %)
Adenosquamous carcinoma 1 (2.6 %) 1 (2.8 %)
Other 3 (7.9 %) 3 (8.3 %)
Pathological stage
IA 10 (26.3 %) 10 (27.8 %)
IB 12 (31.6 %) 10 (27.8 %)
IIA 8 (21.1 %) 8 (22.2 %)
IIB 4 (10.5 %) 4 (11.1 %)
IIIA 2 (5.3 %) 2 (5. %)
IIIB 0 (0.0 %) 0 (0.0 %)
IV 1 (2.6 %) 1 (2.8 %)
(non-cancer) 1 (2.6 %) 1 (2.8 %)
Iwata et al. Respiratory Research  (2016) 17:90 Page 4 of 8
aminotransferase and 1 case of hyponatremia were re-
ported as grade 3; 1 case of anorexia, 1 case of respiratory
failure, and 1 case of dyspnea were reported as grade 4;
and 1 case of pneumonitis was reported as grade 5. The
grade 4 respiratory failure and dyspnea and the grade 5
pneumonitis were determined to be due to AE-IPF.
Among the 43 registered patients who received
pirfenidone, 41 cases underwent surgery (95.3 %). The
reasons for the two surgery cancellations were discovery
of metastatic lesions and necessity of cardiovascular
surgery prior to lung surgery. Surgery was not cancelled
in any patients due to pirfenidone-related adverse events.
Efficacy
AE-IPF was diagnosed in two patients (94.9 % [95 %
confidential interval (CI): 82.7–99.4 %, p = 0.01 under
the null rate of 80 %]) in the FAS (Table 4). The central
review board confirmed both of these cases as AE-IPF.
Both patients died due to AE-IPF. One patient had quit
pirfenidone administration prior to surgery; therefore,
AE-IPF was recognized in only one patient (97.2 %
[95 % CI: 85.5–99.9 %, p = 0.004 under the null rate of
80 %]) in the PPS. Among patients in the PPS, we also
analyzed select IPF cases whose diagnoses were confirmed
by the central review board (PPS-IPF). In the PPS-IPF, one
Table 3 Complications during the study
Preoperative complications (n = 43) Postoperative complications (n = 37)
Grade 1, 2 Grade 3–5 Grade 1, 2 Grade 3–5
Photosensitivity 1 0 0.0 % 0 0 0.0 %
Anorexia 4 0 0.0 % 5 1 (Grade 4, 2.7 %)
Nausea 4 0 0.0 % 3 0 0.0 %
Diarrhea 0 0 0.0 % 1 0 0.0 %
Somnolence 1 0 0.0 % 0 0 0.0 %
Dizziness 2 0 0.0 % 1 0 0.0 %
Malaise 2 0 0.0 % 2 0 0.0 %
Respiratory failure 0 0 0.0 % 0 1 (Grade 4, 2.7 %)
Dyspnea 0 0 0.0 % 5 1 (Grade 4, 2.7 %)
Pulmonary fistula 0 0 0.0 % 2 0 0.0 %
Postoperative hemorrhage 0 0 0.0 % 1 0 0.0 %
Cough 0 0 0.0 % 1 0 0.0 %
Atrial fibrillation 0 0 0.0 % 1 0 0.0 %
Wound dehiscence 0 0 0.0 % 1 0 0.0 %
Pneumonitis 0 0 0.0 % 0 1 (Grade 5, 2.7 %)
Dysgeusia 0 0 0.0 % 1 0 0.0 %
White blood cell decreased 0 0 0.0 % 2 0 0.0 %
Neutrophil count decreased 0 0 0.0 % 1 0 0.0 %
Anemia 2 0 0.0 % 4 0 0.0 %
Hypoalbuminemia 2 0 0.0 % 19 0 0.0 %
ALP increased 2 0 0.0 % 8 0 0.0 %
Blood bilirubin increased 0 0 0.0 % 1 0 0.0 %
AST increased 3 0 0.0 % 8 1 (Grade 3, 2.7 %)
ALT increased 3 0 0.0 % 6 0 0.0 %
GGT increased 5 0 0.0 % 6 0 0.0 %
Creatinine increased 1 0 0.0 % 0 0 0.0 %
Hyponatremia 3 0 0.0 % 8 1 (Grade 3, 2.7 %)
Hyperkalemia 1 0 0.0 % 0 0 0.0 %
Hypokalemia 0 0 0.0 % 3 0 0.0 %
Hypocalcemia 0 0 0.0 % 3 0 0.0 %
ALP alkaline phosphatase, AST aspartate aminotransferase, ALT alanine aminotransferase, GGT γ-glutamyltransferase
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of the 32 patients experienced AE-IPF (96.9 % [95 % CI:
83.8–99.9 %, p = 0.008 under the null rate of 80 %]). When
compared to the threshold derived from historical
controls, AE-IPF occurred at a significantly lower
incidence in this study.
Discussion
The current study was designed to evaluate the safety and
efficacy of perioperative pirfenidone treatment in the
reduction of postoperative AE-IPF in patients with lung
cancer. No serious adverse events caused by pirfenidone
were observed, and the incidence of AE-IPF among pa-
tients treated with pirfenidone was significantly lower than
the null hypothesis.
The incidence of lung cancer have been reported to
be >7-fold higher in IPF patients compared to the
general population [1]. Conversely, IPF is detected in
3.7 % to 8 % of lung cancer patients [14, 19–21]. The
prognosis of lung cancer with IPF is reported to be
worse than that without IPF [14, 19, 22]. Moreover, life-
threatening AE-IPF sometimes occurs as a complication
of lung cancer therapy. Radiation and chemotherapy are
also known to be risk factors for AE-IPF [23–25].
Although the reason for the poor prognosis of lung cancer
patients with IPF is not clear, therapeutic limitations asso-
ciated with the potential of AE-IPF might at least partially
account for the higher recurrence rate. If an effective strat-
egy to reduce AE-IPF is established, more rational and
radical treatment could be delivered to patients in a safer
manner, which would lead to improved patient outcomes.
No studies have yet demonstrated that any agents can
prevent or decrease the incidence of postoperative AE-IPF
[20]. Pirfenidone is the first anti-fibrotic agent approved for
the treatment of IPF [18]. The pooled data from the AS-
CEND and CAPACITY [26] trials showed that death
related to IPF was significantly reduced among patients
receiving pirfenidone therapy [12]. A phase II Japanese
study found that pirfenidone prevented the development
of AE-IPF [27]. However, these randomized studies evalu-
ated the effect of pirfenidone in the context of the natural
history of IPF. The effects of pirfenidone in patients under-
going anticancer therapy such as surgery, radiation, and
chemotherapy, which are all risk factors for AE-IPF, have
previously been unknown. We evaluated perioperative
pirfenidone treatment within a single institute, and the
results of this experience with a small sample size
suggested that it is a feasible treatment and can be ex-
pected to reduce the incidence AE-IPF [28]. Therefore, we
planned this multi-institutional prospective study to con-
firm our previous results.
Although AE-IPF is a well-known, life-threatening
postoperative complication in patients with lung cancer
accompanied by IPF, its reported incidence varies among
studies; however, it generally ranges from 10 % to 20 %
[2–5, 7, 14, 15, 19, 29, 30]. Compared to many small
studies that evaluated 10–60 cases, Yoshimura et al. [5]
reported the largest series of 205 IPF patients with lung
cancer. In this study, these investigators observed that
41 patients (20 %) developed AE-IPF postoperatively,
among which 29 (71 %) died of respiratory failure due to
AE-IPF. In the current study, an 80 % non-exacerbation
rate was set as the null hypothesis based on these previ-
ous reports, which were published prior to the planning
of the current protocol in 2010; the non–AE rates in the
current study of 94.9 % (FAS), 97.2 % (PPS), and 96.9 %
(PPS-IPF) were statistically positive compared to this
null hypothesis.
Several studies have revealed that interstitial pneu-
monia subtype (UIP pattern or not) is a risk factor for
postoperative AE-IPF [10, 31]. However, interstitial
pneumonia subtypes were diagnosed with varying
diagnostic criteria among different institutions in these
previous studies. To circumvent this problem, we
introduced a central review system to confirm the
diagnosis of IPF following the international guidelines.
As a result, we were able to show ~90 % diagnostic
accuracy for each of the participating institutes. We
believe that this first multi-institutional prospective
study to evaluate postoperative AE-IPF after lung
cancer surgery revealed reliable objective data about
the incidence of AE-IPF; these data can be used as a
standard when designing future studies.
Limitations
This study was not randomized but rather was a single-
arm study in which historical data served as the control.
When we combined the Japanese and international data
for surgical lung cancer patients with idiopathic interstitial
pneumonia published prior to the planning of the present
study, the total incidence of AE was about 19 % (data not
shown); therefore, we believe the null hypothesis set
herein was appropriate. However, patient background and
Table 4 Efficacy
Group N AE-IPF occurred within the 30th POD Non–AE rate within the 30th POD 95 % CI p-value
FAS 39 2 94.90 % 82.7–99.4 p = 0.010
PPS 36 1 97.20 % 85.5–99.9 p = 0.004
PPS-IPF 32 1 96.90 % 83.8–99.9 p = 0.008
AE-IPF acute exacerbation of idiopathic pulmonary fibrosis, POD postoperative day, FAS full analysis set, PPS per protocol set, PPS-IPF PPS excluding non-IPF cases
diagnosed by the central review committee
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the influence of some types of patient management that
may have been better than those reported in the literature
could not be controlled in such a single-arm study.
Because the reported background risks for AE also varied
among studies, it is difficult to verify the difference
between the background risk in this study and those of
previous studies. For example, respiratory function and ac-
tivity shown by Hugh-Jones classification of the registered
patients were relatively good in the current study. Severe
IPF is undoubtedly considered to be a high risk; however,
functionally inoperable cases were not included in this
surgical study, and in many cases IPF was newly detected
by surgeons during preoperative examination. Perhaps
due to such a situation bias, the previously reported pre-
operative respiratory functions were also almost normal
[4, 14, 15, 19, 28–31]. Postoperative AE occurs despite
such surgical selection bias. To overcome such back-
ground problems and to confirm the efficacy of periopera-
tive pirfenidone treatment for postoperative AE-IPF, a
randomized study is required. Despite this limitation, we
believe that the positive results of this phase II study
justify the planning of a phase III randomized study.
Conclusions
In conclusion, this single-arm phase II study revealed
that perioperative pirfenidone treatment is safe and
promising for reducing AE-IPF after lung cancer surgery.
These results encourage the planning of future con-
firmatory studies to compare pirfenidone to other
treatments, such as nintedanib, for which the efficacy
against progression of IPF has already been reported [32].
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